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Tuberculous peritonitisAbstract Mycobacterium tuberculous peritonitis is a less common cause of
peritoneal dialysis related infection in developed countries. As both CAPD and APD
are being used as renal replacement therapy in developing countries of South Asia,
Mycobacterium tuberculous peritonitis are being reported. Any culture negative
peritonitis should be investigated for this entity. In this manuscript, we report an
index case and our experience with literature review of Mycobacterium tuberculous
peritonitis. The diagnostic techniques, management and outcome are described.
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244 A. Rohit, G. Abrahameffluent, and specimen from a dry abdomen [1].1. Case report
A 68-year-old male with diabetic nephropathy,
hypertension, and Stage V chronic kidney disease,
initiated on continuous ambulatory peritoneal dial-
ysis (CAPD) in October 2012, presented 2 years
later with cloudy fluid, effluent white blood cell
count 680 cells/mm3 composed of 98% polymor-
phonuclear leukocytes and 2% lymphocytes. Peri-
toneal dialysis (PD) effluent gram stain, routine
culture, acid-fast bacilli smear were negative.
There was no exit site or tunnel infection. Chest
X-ray was unremarkable. He was treated with IP
ceftazidime and cefazolin for 8 days; Intra
Peritoneal (IP) amikacin was added in place of
cefazolin for 2 days along with IV metronidazole
and oral fluconazole 150 mg on alternate days. On
Day 9, in view of nonresolving peritonitis, the PD
catheter was removed and catheter tip gram stain,
culture, and acid-fast bacilli smear were negative.
A peritoneal biopsy during catheter removal
showed no granuloma and tuberculosis (TB)
polymerase chain reaction (PCR) was negative. He
was switched over to hemodialysis and succumbed
to cardiac arrest the following day. Effluent fluid
mycobacterial culture grew Mycobacterium tuber-
culosis on Lowenstein Jensen medium 5 weeks
later (Fig. 1).
2. Introduction
One of the infective complications of CAPD that
causes failure of this modality requiring switch over
to hemodialysis is peritonitis. This leads to tech-
nique failure, peritoneal membrane failure, hospi-
talization and increased mortality. Other causes
for cloudy effluent include chemical peritonitis,
eosinophilia of the effluent, malignancy, chylousFig. 1 Mycobacterium tuberculosis grown on Lowen-
stein Jensen slant from peritoneal dialysis (PD) fluid of a
68-year-old patient. TB = tuberculosis.Culture negative peritonitis may be another cause
of cloudy fluid. Hence, the International Society
for Peritoneal Dialysis (ISPD) guidelines indicate
that culture negative peritonitis should not exceed
20% of episodes [1]. Culture negative peritonitis
could also be due to prior use of antibiotics, low vol-
ume of effluent fluid, use of inappropriate media
for culture, and rarely, the presence of uncultur-
able organisms. Studies have shown that automated
culture improves yield compared with conventional
culture [2].
3. Peritonitis due to mycobacteria
Although an infrequent cause of peritonitis (<3%),
Mycobacterial peritonitis is not uncommon in
Southeast Asian countries. Special attention is
required to diagnose Mycobacterial peritonitis
which has been shown to have a higher incidence
in developing countries in Asia and Africa [3]. The
initial inflammatory response to peritonitis due to
bacterial, mycobacterial, and fungal etiology is
predominantly polymorphonuclear leukocytosis,
thus making it difficult to diagnose. Peritonitis
due to Mycobacteria may be due to M. tuberculosis
or nontubercular Mycobacteria. Thus, routine test-
ing for new infections in culture negative cases or
for coinfection is vital. This may also lead to single
agent therapy without full recovery [4].
4. Our experience
In 2014, we analyzed 92 bags with suspected peri-
tonitis. Of these, 26 had bacterial growth. Tuber-
culous peritonitis was suspected in 15 patients.
Of these, five patients (26%) were smear and cul-
ture positive (Table 1). Our rate of tuberculous
peritonitis in 2014 was 6.52%. TB PCR (Gene Xpert,
Cepheid, Sunnyvale, USA) was carried out for eight
patients. Of these, four were positive. Of the four
patients with positive PCR, smear and culture also
was positive in two patients. Results of TB PCR cor-
related with culture in all but one case where the
patient died due to a delay in diagnosis. This sam-
ple was also smear negative but culture positive.
We performed a retrospective analysis on the
old records that we held between 2000 and 2011
and found a total of 34 patients (20 male and 14
female) who had been diagnosed with tuberculous
peritonitis. The average time for development of
peritonitis was about 10 months. Thirty-eight per-
cent (13) of patients were diabetic, 26% (9) were
hypertensive, 23.5% (8) had cardiac disease, 6%
Table 1 Review of cases diagnosed with Tuberculous peritonitis in 2014.
SL. No. Patient demographics Diagnostic
modality





1 65 y/female Smear+ 2 mo 5 mo of ATT then patient
lost to follow-up
Yes Patient on PD for very small
duration
2 60 y/male Smear+ Recurrent peritonitis since
the past 2 y with CoNS. On
repeated courses of
antibiotics






3 28 y/female Smear+ Recent catheter insertion (2
mo prior). 1 episode of
bacterial peritonitis 1 mo
prior
Ongoing treatment No Patient doing well
4 57 y/male TB PCR positive TB PCR of fluid +ve on
several occasions over
4 years
No growth on culture
Patient expired on third
episode of tuberculous
peritonitis
No Possibility of drug resistant
TB in 2010 and 2011 but no
culture and no gene Xpert
then. Hence unconfirmed
5 64 y/female TB PCR positive Clinically suggestive of TB Expired 5 mo later No Presented with pain and
tenderness. No clinical
relevance of the diagnosis
with TB
6 68 y/male Culture positive Diagnosis made
posthumously from PD fluid
5 wk after patient expired
No treatment since
diagnosis was posthumous
Yes Membrane biopsy culture
negative



















Fig. 2 Hematoxylin and eosin 100 showing granulo-
matous inflammation with ill-defined epithelioid cell
granuloma and Langhans’ cell multinucleated giant cell.
246 A. Rohit, G. Abraham(2) had a cardiovascular accident (CVA), and others
had no comorbidities. Diagnostic tools such as PCR
were used along with conventional culture tech-
niques in all cases; molecular diagnostic techniques
yielded positive results in 82.3% of the cases
whereas only 20.5% cases were detected with
smear and culture for acid fast bacilli. Only two
patients had catheter removal due to tubercular
peritonitis and no mortality was recorded [4].
Although PCR has shown us promising results, its
application in routine diagnostics faces problems
such as contamination and complicated procedure
for sample preparation.
Amaro et al. [5] found that due to the complex
cell wall structure of M. tuberculosis, the com-
bined bead beating and enzymatic extraction
method was the most efficient and easy method
of mycobacterial DNA extraction.
It has been our experience that patients present
with a coinfection of tuberculous peritonitis along
with bacterial peritonitis or fungal peritonitis [4].
Hence, the risk factors for developing
superimposed TB peritonitis include malnutrition,
diabetes, partially treated TB, scars on chest
X-ray, and patients who are immunosuppressed.
M. tuberculous peritonitis may be diagnosed from
culturing PD fluid or culture of peritoneal mem-
brane when biopsied. Peritoneal biopsy culture
while removing PD catheter for peritonitis or while
implanting a new catheter may show a caseating
granuloma or a fungus, and hence may be useful
in the diagnosis of TB or fungal peritonitis as in
our experience [6] (Fig. 2). In the case discussed
above, the peritoneal biopsy showed no granuloma
which may be a sampling bias. However, the PD
fluid grew TB bacilli after 5 weeks of incubation.
Sampling error of the peritoneal biopsy may leadto false negatives. Early diagnosis and therapy
improve the outcome, minimizing membrane dam-
age and ultrafiltration failure. This also improves
nutritional status, thereby reducing morbidity and
mortality. TB peritonitis may be also due to nontu-
bercular Mycobacterium as is described in ISPD
guidelines [1].
5. Review of literature
Mycobacterium spp. remains a significant cause of
morbidity and mortality worldwide, with over 3
million deaths per year. Large pools of latently
infected cases, difficult to diagnose, and long
duration of treatment represent challenges in
controlling this organism.
End stage renal disease patients are at an
increased risk of developing TB due to their deficit
in cell-mediated immunity. Furthermore, dialysis
effluent which is bioincompatible with increased
glucose concentration with nonphysiological pH,
and osmolality can impair phagocytic function
and lymphocytic activity of the peritoneum due
to organisms even with a smaller inoculums size
[7].
Talwani and Horvath [8] studied Mycobacterial
peritonitis literature from 1976 to 1999 and identi-
fied 52 cases associated with CAPD; 13% of these
were from the USA and 54% were diagnosed in
the Asian subcontinent. According to their analysis,
TB was considered a statistically significant predic-
tor for death in these patients. Further, delay in
treatment by 4 weeks caused a significant
difference in the outcome of the patients, includ-
ing mortality. Duration of treatment varied
between 6 months and 12 months [8]. In our expe-
rience, two diabetic patients on CAPD who had
treatment for <12 months duration had recurrence
of tuberculous peritonitis. This highlights the
importance of treating tuberculous peritonitis for
at least 12 months.
Akpolat [9], noted that most of the cases of
tuberculous peritonitis had been reported from
Hong Kong, closely followed by Turkey and India.
The authors concluded that early diagnosis and
timely initiation of antitubercular drugs was the
key to effective management of tuberculous
peritonitis [9].
Abraham et al. [4] conducted a prospective
study of 155 patients who were initiated into CAPD
until 2001. In their cohort, four patients (2 men and
2 women) developed tuberculous peritonitis. These
patients had been on PD for a duration of
2–84 months. The authors concluded that
although TB peritonitis constituted a mere 1–2%
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peritonitis, a high index of suspicion of TB is
required. The various methodologies for diagnosis
include Ziehl–Neelsen stained smear, culture,
and PCR [4]. The yield by smear and culture is very
low and hence a more sensitive methodology may
be needed to arrive at the diagnosis.
Another interesting paper by Vadivel et al. [7]
compared the incidence of TB among immigrants
and native Americans and Europeans. They found
that the incidence of tuberculous peritonitis in
immigrants from endemic areas like the Indian sub-
continent increased to 13% as compared with 1–6%
in native people. They concluded that all efforts
should be made to rule out TB peritonitis in
patients with prolonged failure to thrive or relaps-
ing peritonitis with negative bacterial cultures, and
in febrile patients with nonresolving peritonitis.
A working group from China made a retrospec-
tive study of patient files spanning 10 years, i.e.,
1996 to 2006. The diagnosis of TB was made with
comparison of smear, culture, and histopathologi-
cal findings. They concluded that since tuberculous
peritonitis presents with nonspecific and protean
manifestations, the differential diagnosis has to
be considered in the context of culture negative
peritonitis or culture positive peritonitis not
responding to appropriate antibiotics [10].
6. Challenges for diagnosis
Diagnosis of tuberculous peritonitis in PD has
always been an Achilles heel. Diagnosis is based
on microscopy which has 50% sensitivity over cul-
ture [3]. Most countries do not even have an infras-
tructure to diagnose TB. A need for a simple, rapid,
robust, and dynamic test for detecting resistance is
essential. Although powerful molecular diagnostic
platforms are emerging, they are fraught with
problems. Delays in sample transport, cost of
procuring and maintaining equipment, and trained
personnel for handling the equipment are just a
few of the issues involved in diagnosis of TB [3].
The various tests available for diagnosis include
microscopy (Ziehl–Neelsen staining and auramine-
rhodamine staining), culture on solid base media
like Lowenstein Jenson slopes, liquid culture on
Middlebrook broth, automated culture on
Mycobacteria growth indicator tube (MGIT) etc.,
PCR for IS6110 gene or manual nucleic acid
amplification technique, Line probe assay (Hain
Lifescience, Germany) for TB by Hain, real time
PCR on various platforms using single nucleotide
polymorphism, gene Xpert MTB (Mycobacterium
tuberculosis)/RIF (Rifampicin Resistance) assay,sequencing, molecular beacons assay, loop-
mediated isothermal amplification, tuberculin skin
test/Mantoux test, among others [11].
Ziehl–Neelsen stained smears and culture on
solid media have been in use for a while. However,
these techniques lack sensitivity and cannot detect
resistance. Studies have now found that liquid
media like Middlebrook broth are better than solid
media like Lowenstein Jensen media, since they
contribute significantly to improve patient man-
agement. Automated culture systems like MGIT
(Bactec, Becton Dickinson, USA) have been devel-
oped, with the advantages of using liquid culture,
thereby reducing the turnaround time along with
drug sensitivity testing, which is made simple and
accurate. The MGIT makes use of modified
Middlebrook 7H9 broth along with sensors. Hence,
the principle of fluorometry is safe and accurate
and has been recommended by the World Health
Organization [11].
However the landscape of TB diagnosis is chang-
ing world over thanks to the roll out of gene Xpert,
genotype line probe assay, and other nucleic acid
based technologies. The involvement of the public
sector has been crucial in developing countries to
improve diagnosis. Gene Xpert has changed the
face of TB diagnosis (pulmonary and extrapul-
monary) world over. It is based on the nucleic acid
amplification technique. It additionally adds infor-
mation about rifampicin resistance [12].
The line probe assay is DNA hybridization based
and adds to information on first line drug resistance
[13]. Diagnosis of latent TB can be made with the
QuantiFERON gold assay (Qiagen, Germany) and
through proteomic technology. However, the use-
fulness of these tests for diagnosis of active TB is
questionable. Moreover, they have not been proven
useful in extrapulmonary samples such as pleural
fluid and PD fluid. Hence, diagnosis of smear nega-
tive extrapulmonary TB remains challenging [11].
7. Treatment and management
The ISPD guidelines are useful for guiding therapy
for tuberculous peritonitis in CAPD. However,
increased duration of therapy as suggested will
help avoid recurrence. TB peritonitis remains a
treatable condition with no real consensus on the
removal of the PD catheter [13]. ISPD recommends
reinsertion of the catheter within 6 weeks if
removal was indicated [1].
Drugs used are isoniazid and rifampicin, which
need to be given for 12–18 months, along with
pyrazinamide and ofloxacin for the first 3 months.
Oral pyridoxine (50–100 mg/d) should be given
248 A. Rohit, G. Abrahamdaily. Rifampicin, however, is found only in low
levels in dialysis fluids due to high molecular
weight, high protein binding capacity, and lipid sol-
ubility, and hence may need to be given via the
intraperitoneal route [1,14].
Data regarding extrapulmonary multidrug
resistant (MDR) TB is limited, with few cases being
described in large case cohorts of MDR TB. The
prevalence of primary MDR TB in India was about
2–3% and 5–15% in previously treated cases. These
patients run a risk of treatment failure due to poor
drug penetration at the site of infection, inaccessi-
bility for surgical intervention, and lack of drug sen-
sitivity testing data from most laboratories. The
emergence and spread of MDR TB can be prevented
by prompt diagnosis and effective therapy. Treat-
ment for MDR-TB lasts for 2 years. Second line drugs
include injectables like streptomycin, kanamycin,
capreomycin and drugs like ofloxacin, moxifloxacin,
levofloxacin, ethionamide, cycloserine, and Para-
aminosalicylic Acid (PAS) [15].
Dialysis effluent after an adequate dwell time
and appropriate length of therapy (usually 2 weeks)
shows clearing of the organism which is better con-
firmed by nucleic acid based tests [4]. Adequate
attention should be paid to the adjunctive role
played by nutrition (energy requirements, protein
requirements, and macronutrient and micronutri-
ent deficiencies) in the success of treatment for
TB. With the emergence of multidrug resistance
and extensive drug resistance, treatment options
become narrow. ISPD has not issued guidelines on
the same.
8. Conclusion
Tuberculous peritonitis is an underdiagnosed
condition due to nonavailability of diagnostic tech-
niques, lack of standardization of the techniques
available, and reduced index of suspicion. Hence,
it is imperative that early diagnosis and appropri-
ate therapy for not less than 12 months with a
multidisciplinary team approach holds the key to
better treatment and outcomes in these patients.
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